Business Description
GlaxoSmithKline Consumer Nigeria PLC
ISIN : NGGLAXOSMTH8
Description
GlaxoSmithKline Consumer Nigeria PLC is a healthcare company that researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products. The company has two reportable segments, the Consumer Healthcare segment consisting of oral care, over-the-counter (OTC) medicines, and nutritional healthcare; and the Pharmaceuticals segment consisting of vaccines and prescription drugs. The company's product line includes panadol, Andrews liver salt, Macleans, ampiclox, Sensodyne, and others. The generates maximum revenue from the Pharmaceuticals segment.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.3 | |||||
| Interest Coverage | 5.64 | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 2.15 | |||||
| Beneish M-Score | -4.11 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 6.9 | |||||
| 3-Year EBITDA Growth Rate | -3.6 | |||||
| 3-Year EPS without NRI Growth Rate | -4.7 | |||||
| 3-Year FCF Growth Rate | 159.5 | |||||
| 3-Year Book Growth Rate | 1.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 82.61 | |||||
| 9-Day RSI | 70.31 | |||||
| 14-Day RSI | 68.41 | |||||
| 6-1 Month Momentum % | 72.59 | |||||
| 12-1 Month Momentum % | 165.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.38 | |||||
| Quick Ratio | 1.27 | |||||
| Cash Ratio | 1.01 | |||||
| Days Inventory | 139.4 | |||||
| Days Sales Outstanding | 108.59 | |||||
| Days Payable | 47.52 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.24 | |||||
| Dividend Payout Ratio | 1.04 | |||||
| 3-Year Dividend Growth Rate | -3.5 | |||||
| Forward Dividend Yield % | 3.24 | |||||
| 5-Year Yield-on-Cost % | 4.4 | |||||
| Shareholder Yield % | 3.24 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 31.46 | |||||
| Operating Margin % | 3.16 | |||||
| Net Margin % | 4.24 | |||||
| FCF Margin % | 49.69 | |||||
| ROE % | 6.54 | |||||
| ROA % | 2.11 | |||||
| ROIC % | 9.61 | |||||
| ROC (Joel Greenblatt) % | 192.53 | |||||
| ROCE % | 9.12 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 34 | |||||
| PE Ratio without NRI | 32.02 | |||||
| Shiller PE Ratio | 11.82 | |||||
| Price-to-Owner-Earnings | 3.14 | |||||
| PEG Ratio | 11.86 | |||||
| PS Ratio | 1.44 | |||||
| PB Ratio | 2.21 | |||||
| Price-to-Tangible-Book | 2.21 | |||||
| Price-to-Free-Cash-Flow | 2.9 | |||||
| Price-to-Operating-Cash-Flow | 2.9 | |||||
| EV-to-EBIT | 2.75 | |||||
| EV-to-EBITDA | 2.56 | |||||
| EV-to-Revenue | 0.16 | |||||
| EV-to-FCF | 0.33 | |||||
| Price-to-Projected-FCF | 0.96 | |||||
| Price-to-Graham-Number | 1.59 | |||||
| Price-to-Net-Current-Asset-Value | 2.57 | |||||
| Price-to-Net-Cash | 130.76 | |||||
| Earnings Yield (Greenblatt) % | 36.36 | |||||
| FCF Yield % | 34.96 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
GlaxoSmithKline Consumer Nigeria PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₦) | 14,302.951 | ||
| EPS (TTM) (₦) | 0.5 | ||
| Beta | 0 | ||
| Volatility % | 131.74 | ||
| 14-Day RSI | 68.41 | ||
| 14-Day ATR (₦) | 0.023579 | ||
| 20-Day SMA (₦) | 16.96 | ||
| 12-1 Month Momentum % | 165.63 | ||
| 52-Week Range (₦) | 5.75 - 17.05 | ||
| Shares Outstanding (Mil) | 1,195.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
GlaxoSmithKline Consumer Nigeria PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
GlaxoSmithKline Consumer Nigeria PLC Stock Events
| Event | Date | Price(₦) | ||
|---|---|---|---|---|
| No Event Data | ||||
GlaxoSmithKline Consumer Nigeria PLC Frequently Asked Questions
What is GlaxoSmithKline Consumer Nigeria PLC(NSA:GLAXOSMITH)'s stock price today?
The current price of NSA:GLAXOSMITH is ₦17.00. The 52 week high of NSA:GLAXOSMITH is ₦17.05 and 52 week low is ₦5.75.
When is next earnings date of GlaxoSmithKline Consumer Nigeria PLC(NSA:GLAXOSMITH)?
The next earnings date of GlaxoSmithKline Consumer Nigeria PLC(NSA:GLAXOSMITH) is .
Does GlaxoSmithKline Consumer Nigeria PLC(NSA:GLAXOSMITH) pay dividends? If so, how much?
The Dividend Yield %  of GlaxoSmithKline Consumer Nigeria PLC(NSA:GLAXOSMITH) is 3.24% (As of Today), Highest Dividend Payout Ratio of GlaxoSmithKline Consumer Nigeria PLC(NSA:GLAXOSMITH) was 1.04. The lowest was 0.15. And the median was 0.67. The  Forward Dividend Yield % of GlaxoSmithKline Consumer Nigeria PLC(NSA:GLAXOSMITH) is 3.24%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers